Skip to content

Depression Prevention in Older Spousally-bereaved Adults

Efficacy of a Healthy Lifestyle Intervention to Reduce Depression in Older Spousally-bereaved Adults

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04016896
Acronym
WELL
Enrollment
151
Registered
2019-07-12
Start date
2020-10-20
Completion date
2025-01-17
Last updated
2026-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Brief summary

Using an indicated prevention approach, investigators propose to enroll 150 spousally-bereaved adults aged 60 years and older in the first 12 months after spousal death who are at high risk for major depression disorder because of subthreshold symptoms of depression. A confirmatory efficacy trial will be conducted in which participants will be randomly assigned to (a) self-monitor sleep, meals, and physical activity for 12 weeks using digital monitoring plus motivational health coaching (WELL; n=75); or (b) enhanced usual care (EUC, usual care plus study assessments, n=75). Objective actigraphic measures of the 24-hour pattern of day and nighttime activity - known as the rest-activity rhythm - will be measured to evaluate circadian rhythms as a mediator of treatment outcomes. Participants will be assessed at baseline, months 1 & 2, post-intervention, and 3, 6,12, 18-months post-intervention. In addition, the investigators will include a subset of participants bereaved by COVID-19 (or suspected as bereaved by COVID-19). Participants in this subset will undergo the same research procedures as the main cohort. Participants in both the main cohort and subset determined to be fully eligible will be randomized into two groups with a total of: enhanced usual care (EUC; n=75) and WELL (WELL; n=75).

Detailed description

The primary aim of this R01 application is to test the efficacy of a new behavioral intervention that targets the timing and regularity of sleep, meals, and physical activity to stabilize circadian rhythms, for reducing symptoms of depression in older acutely-bereaved adults. This trial began at the onset of the SARS-CoV-2/COVID-19 pandemic when grief and loss where ubiquitous and access to mourning services was limited. To test whether this intervention could reduce the severity of associated psychopathological conditions common after spousal death, we added secondary outcomes of anxiety, complicated grief, and posttraumatic stress.

Interventions

BEHAVIORALWIdowed Elders' LIfestyle after Loss (WELL)

Digital monitoring of sleep, meals, physical activity (daily); motivational health coaching (weekly); and web-based performance feedback (in real-time) for 12 weeks.

OTHEREnhanced Usual Care

Health education, referral to mental health support, and telephone-delivered support (weekly) for 12 weeks.

Sponsors

University of Pittsburgh
Lead SponsorOTHER
National Institute of Mental Health (NIMH)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* aged 60 years and older; * spousally (or partner) bereaved up to 12 months (includes bereaved as a result of COVID-19); * at-risk for major depressive disorder (MDD), based on high-risk markers defined as subthreshold symptoms of depression (Hamilton Depression Rating Scale score of \> or = 9), together with absence of current MDD, post-traumatic stress disorder, or persistent complex bereavement disorder

Exclusion criteria

* current Diagnostic and Statistical Manual Diploma in Social Medicine (DSM-5) criteria for syndromal mood, psychosis within the last 12 months; * dementia/cognitive impairment; Telephone Interview Cognitive Screening (TICS) \<19; * acute suicide risk; based on Herbeck et al. protocol for suicide risk management; * patients taking new psychotropic medications after spousal death to stabilize depression including antidepressants and benzodiazepines \>4 days/week for more than two months. Individuals who have been on a stable dose for at least 1 month and agree not to change during participation, unless it is medically necessary, will be included.

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline in Depression Symptom Burden at 3 Monthsbaseline vs. 3 monthsDepression symptoms measured by the clinician administered Hamilton Rating Scale for Depression

Secondary

MeasureTime frameDescription
Change From Baseline in Anxiety Symptom Burden at 3 Monthsbaseline vs. 3 monthsAnxiety symptoms measured with the Generalized Anxiety Disorder - 7
Change From Baseline in Complicated Grief Symptom Burden at 3 Monthsbaseline vs. 3 monthsComplicated grief symptoms measured with the Inventory of Complicated Grief
Change From Baseline in Posttraumatic Stress Symptom Burden at 3 Monthsbaseline vs. 3 monthsPosttraumatic stress symptoms measured with the PTSD Checklist for DSM-5

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORsarah t stahl, PhD

University of Pittsburgh

Participant flow

Recruitment details

Participants were recruited from university-affiliated research registries, social media, local hospice organizations, grief support groups, and specialty-care medicine at the University of Pittsburgh Medical Center.

Pre-assignment details

Participants were randomized 1:1 to intervention or control.

Baseline characteristics

Characteristic
Age, Continuous70.3 years
STANDARD_DEVIATION 6.8
Anxiety symptoms3.5 score on a scale
STANDARD_DEVIATION 3.3
Complicated grief symptoms23.4 score on a scale
STANDARD_DEVIATION 11.1
Depressive symptoms3.0 score on a scale
STANDARD_DEVIATION 3.2
Posttraumatic stress symptoms14.8 score on a scale
STANDARD_DEVIATION 10.4
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
2 Participants
Race (NIH/OMB)
Black or African American
15 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
66 Participants
Sex: Female, Male
Female
61 Participants
Sex: Female, Male
Male
15 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 750 / 76
other
Total, other adverse events
34 / 7535 / 76
serious
Total, serious adverse events
4 / 754 / 76

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026